他汀使用、肌少症发生与腹主动脉瘤腔内修复术后长期生存
该回顾性研究纳入2006至2014年在芬兰Tampere大学医院接受EVAR的216例腹主动脉瘤患者,分析他汀使用与腰大肌参数变化及全因死亡的关系。中位随访6.3年,总死亡率54.2%;
要点
- 他汀使用者EVAR术后长期全因死亡率显著低于非使用者(HR 0.69)。
- 他汀使用未导致腰大肌面积或密度等肌少症指标恶化。
- 他汀使用者腰大肌面积相对下降幅度反而更小(-15.7% vs -21.1%)。
核心结论
- 他汀使用与EVAR术后长期全因死亡率降低相关,且不增加肌少症风险。
研究设计与样本
- 回顾性研究纳入2006至2014年芬兰Tampere大学医院接受EVAR的216例腹主动脉瘤患者。
- 从基线和主要1至3年随访CT评估L3水平腰大肌参数,用Cox回归分析他汀、腰大肌变化与全因死亡的关系。
主要发现
- 患者87%为男性,平均年龄77.7岁(标准差7.4),中位随访6.3年(四分位距3.5),总死亡率54.2%(n=117)。
临床怎么用
- 对接受EVAR的腹主动脉瘤患者,他汀治疗可能带来长期生存获益且不加重肌少症。
- 评估他汀获益时无需过度担忧其导致肌少症而影响远期生存。
局限性
- 回顾性研究设计,样本来自单一中心,样本量216例。
- 他汀使用为非随机分组,可能存在残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Statin therapy, associated with improved short-term survival after treatment of abdominal aortic aneurysms, may also predispose to muscle side effects. Evidence on statin-related sarcopenia is limited mainly to muscle function, and it is subject to several sources of bias. In the long term, postoperative development of sarcopenia is linked to mortality after endovascular repair (EVAR). We investigated statin use and long-term postoperative mortality after EVAR in relation to objective measurable markers of sarcopenia (psoas muscle surface area and density). METHODS: Altogether 216 abdominal aortic aneurysm patients treated with EVAR between 2006 and 2014 at Tampere University Hospital (Finland) were retrospectively studied. Psoas muscle parameters at the L3 level were evaluated from baseline and mainly 1- to 3-year follow-up computed tomography studies. Cox regression was used to study the association between statin medication, psoas muscle changes, and all-cause mortality. RESULTS: The majority of patients were male (87%), and the mean age was 77.7 years (standard deviation, 7.4). The median duration of follow-up was 6.3 years (interquartile range, 3.5) with a total mortality of 54.2% (n = 117). Regardless of a higher burden of comorbidities, statin users (n = 119) had lower mortality when compared with nonusers (multivariable hazard ratio [HR]: 0.69, 95% confidence interval: 0.48-0.99, P = .048). Furthermore, statin use was not associated with inferior muscle parameter values, and the relative change in psoas muscle area was actually lower in statin users compared with nonusers (-15.7% and -21.1%, P < .046). CONCLUSIONS: Statin use is associated with lower long-term mortality among patients undergoing EVAR without predisposing to increased sarcopenia.
引用
- Lindström I, Protto S, Khan N, et al. Statin use, development of sarcopenia, and long-term survival after endovascular aortic repair. J Vasc Surg. 2021. PMID: 34019985. doi:10.1016/j.jvs.2021.04.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。